

Nelida Ines Noguera

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1284640/publications.pdf>

Version: 2024-02-01

21
papers

665
citations

759233

12
h-index

713466

21
g-index

22
all docs

22
docs citations

22
times ranked

1026
citing authors

#	ARTICLE	IF	CITATIONS
1	CD99 as a novel therapeutic target on leukemic progenitor cells in FLT3-ITDmut AML. <i>Leukemia</i> , 2022, , .	7.2	2
2	Ascorbate Plus Buformin in AML: A Metabolic Targeted Treatment. <i>Cancers</i> , 2022, 14, 2565.	3.7	12
3	Absence of FGFR3â€“TACC3 rearrangement in hematological malignancies with numerical chromosomal alteration. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 163-168.	0.9	3
4	PML/RARa Interferes with NRF2 Transcriptional Activity Increasing the Sensitivity to Ascorbate of Acute Promyelocytic Leukemia Cells. <i>Cancers</i> , 2020, 12, 95.	3.7	10
5	NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020083.	1.3	6
6	Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. <i>Cells</i> , 2020, 9, 2423.	4.1	12
7	<scp>PML</scp>/<scp>RARA</scp> inhibits expression of <scp>HSP</scp>90 and its target <scp>AKT</scp>. <i>British Journal of Haematology</i> , 2019, 184, 937-948.	2.5	11
8	Acute Promyelocytic Leukemia: Update on the Mechanisms of Leukemogenesis, Resistance and on Innovative Treatment Strategies. <i>Cancers</i> , 2019, 11, 1591.	3.7	70
9	Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress. <i>Leukemia</i> , 2018, 32, 285-294.	7.2	37
10	The forkhead box C1 (FOXC1) transcription factor is downregulated in acute promyelocytic leukemia. <i>Oncotarget</i> , 2017, 8, 84074-84085.	1.8	4
11	A case of SRSF2 mutation in chronic lymphocytic leukemia. <i>Leukemia Research Reports</i> , 2016, 6, 11-14.	0.4	2
12	PML nuclear body disruption impairs DNA double-strand break sensing and repair in APL. <i>Cell Death and Disease</i> , 2016, 7, e2308-e2308.	6.3	36
13	PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity. <i>Oncotarget</i> , 2016, 7, 66386-66397.	1.8	19
14	Cytotoxic effects of high concentrations of sodium ascorbate on human myeloid cell lines. <i>Annals of Hematology</i> , 2015, 94, 1807-1816.	1.8	31
15	Benznidazole modulates cell proliferation in acute leukemia cells. <i>Immunopharmacology and Immunotoxicology</i> , 2013, 35, 478-486.	2.4	6
16	Nucleophosmin/B26 regulates PTEN through interaction with HAUSP in acute myeloid leukemia. <i>Leukemia</i> , 2013, 27, 1037-1043.	7.2	45
17	Detection of the nucleophosmin gene mutations in acute myelogenous leukemia through RTâ€“PCR and polyacrylamide gel electrophoresis. <i>European Journal of Haematology</i> , 2009, 82, 69-72.	2.2	12
18	Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin. <i>Clinical Advances in Hematology and Oncology</i> , 2006, 4, 57-62, 76-7.	0.3	21

#	ARTICLE	IF	CITATIONS
19	Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia. <i>Leukemia</i> , 2005, 19, 1479-1482.	7.2	112
20	Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy. <i>Haematologica</i> , 2004, 89, 29-33.	3.5	31
21	Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. <i>Leukemia</i> , 2002, 16, 2185-2189.	7.2	176